CellBion Co., Ltd.

CellBion Co., Ltd. is a biotechnology company focused on the research and development of radiopharmaceutical products. Its clinical-stage pipeline includes 177Lu-PSMA-DGUL for prostate cancer radiotherapy (Phase 2), 225Ac-Antibody for multiple cancer types (pre-clinical), 225Ac-DGUL for prostate cancer radiotherapy (pre-clinical), 68Ga-Nota-MSA for cardiovascular disease diagnosis (Phase 2), 99mTc-MSA-ICG for lymphoscintigraphy SLN mapping (Phase 1), and 68Ga-NGUL for prostate cancer diagnosis (Phase 2). The company is also developing a pre-clinical pipeline comprising 68Ga-FAP for solid tumor diagnosis, 225Ac-FAP for solid tumor radiotherapy, and peptide-based radioligand therapy and antibody-radionuclide conjugates for undisclosed indications. Founded in 2010, CellBion is headquartered in Seoul, South Korea.